🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in South Korea / NCT07539883
Recruiting Observational

Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study

NCT07539883 · tracked via the Priya Life Science South Korea tracker
Phase
Observational
Started
2026-01-22
Last updated
2026-04-20

Condition(s) studied

Septic ShockMultiorgan FailureSepsis

Study summary

This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 19 years or older. * Admitted to the ICU with septic shock (Sepsis-3 criteria) between March 2021 and August 2025. * Required Continuous Renal Replacement Therapy (CRRT) due to acute kidney injury (AKI). Exclusion Criteria: * Death or withdrawal of life-sustaining therapy within 48 hours of ICU admission. * Patients with End-Stage Renal Disease (ESRD). * Patients with missing critical covariates.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do Recruiting

More Seoul National University Bundang Hospital trials in South Korea

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07539883 on ClinicalTrials.gov ↗ ← All trials in South Korea